Welcome!

News Feed Item

Hard to Treat Depression Patients Recover Completely With Magnetic Therapy

LONDON, July 2, 2013 /PRNewswire/ --


Leading  London Centre  presents first 'real world' UK data, supporting effectiveness of  repetitive Transcranial Magnetic Stimulation  for the treatment of major depression

 

Data from the first 'real-world' treatment audit presented today at The Royal College of Psychiatrists' International Congress 2013 in Edinburgh show that 60% of patients with treatment-resistant depression achieved complete remission (patients report and show no symptoms) when treated with repetitive Transcranial Magnetic Stimulation (rTMS).[1] These data are in-line with results reported in major treatment centres in the US and Canada.

Results from the 'real-world' audit of the first ten UK patients to be treated with rTMS at The London Psychiatry Centre, showed that six of the ten patients assessed achieved no anxiety or depression symptoms at the end of the treatment. Furthermore, one other patient responded to treatment as indicated by a 50% reduction in their depression score. All patients tolerated the treatments well with no significant side effects, with two subjects reporting an occasional mild headache, responding to paracetaomol.[1]  

Dr Rafael Euba, Consultant Psychiatrist at the Centre said, "These data reinforce the body of existing worldwide evidence for rTMS and its proven ability to treat depressed patients who have not responded to drug treatment and/or therapy."

rTMS is a painless and non-invasive method of brain stimulation that relies on electromagnetic induction using an insulated coil placed over the scalp, focused on an area of the brain thought to play a role in mood regulation.[2] Treatment with rTMS is licenced in the UK for adults with depression who have failed to achieve satisfactory improvement from two prior antidepressant medications, at or above the minimal effective dose and duration in the current episode. For these patients, rTMS provides an effective and pain-free alternative to experience relief from depression, without the side-effects that may be associated with more extreme or chemical alternatives.[3],[4],[5],[6],[7] Offered widely at high profile hospitals and centres in the US, including John Hopkins and Harvard's McLean Hospital, The London Psychiatry Centre is the first and only clinic to offer rTMS treatment in the UK.

One of the patients who recently completed the four week treatment said, "The treatment shifted the way I approach problems and almost blocks my negative way of thinking. I feel like the person I used to be 30 years ago! I've got my brain back!" After two weeks of treatment, not only had the patient stopped taking her medication completely, she no longer felt the dread she woke up with every day and decided to start doing new things, feeling optimistic about her future.

Around one in ten people in the UK suffer from depression at some point in their lifetime, which is over six million people, a number equivalent to the entire population of Scotland. More frequently prescribed treatments don't always work or are not suitable, plus their side-effects can cause weight gain, low sex drive and even heart problems. Up to 70% of people with depression will continue to experience symptoms despite taking medication and/or receiving psychotherapy. This is known as treatment-resistant depression, which is very common.

According to larger international clinical studies, one in two patients who were unresponsive to antidepressant medication experience a significant improvement in their depressive symptoms when treated with rTMS, while 1 in 3 experiences recovery.[6] Patients with resistant depression treated with rTMS also benefited from a shorter recovery time of around 4 weeks. This compares to those trying alternative medications that would typically experience improvements in around 6-9 months, if recognised treatment protocols are followed.

A further 13 patients have been treated with rTMS since the audit presented today, with all of them achieving complete remission within 4 weeks.  An audit of all 23 patients treated showed that 78% of the patients treated at The London Psychiatry Centre with rTMS achieved complete remission, a further 9% improved but did not achieve remission and 13% did not improve.[8]

If you or a person you know would like to find out more information about treatment with rTMS visit The London Psychiatry website at http://www.psychiatrycentre.co.uk.

Notes to Editors

About depression

Around one in ten people in the UK suffer needlessly from depression at some point in their lifetime and it is thought that a large number of people are still undiagnosed. The condition can impact every aspect of a person's life including their ability to work, establish and maintain relationships and their overall quality of life. Depression has also been associated with an increased risk of cardiovascular disease, such as heart attack and stroke.[9],[10],[11],[12]

About rTMS

rTMS is a non-invasive method of brain stimulation that relies on electromagnetic induction using an insulated coil placed over the scalp, focused on an area of the brain thought to play a role in mood regulation.[13] The coil generates brief magnetic pulses, which pass easily and painlessly through the skull and into the brain. The pulses generated are comparable to those generated by magnetic resonance imaging (MRI) machines. When these pulses are administered in rapid succession, it is referred to as "repetitive TMS " or "rTMS", which can produce longer lasting changes in brain activity.[4]Clinical studies have consistently shown that rTMS is effective in treatment-resistant depression,[6],[14],[15],[16],[17],[18],[19],[20].rTMS has been licensed in the UK to treat patients with depression who have not seen a satisfactory response to 2 antidepressants.

In comparison to more extreme alternatives such as electroconvulsive therapy (ECT), rTMS is considerably less invasive, has minimal side effects,[21] and has proven to offer equivalent health benefits.[22] rTMS is therefore seen as a safe middle step in people who do not respond to antidepressants, before considering ECT. In the US, rTMS is offered as a standard therapy in a number of high profile health clinics including John Hopkins and the Mayo Clinic.  

rTMS treatment is well tolerated and non-invasive, requiring only five sessions per week for between two to  six weeks, sometimes followed by maintenance or top-up treatment 6 -12 months later.[19],[20] Patients also recover faster in around 4 weeks, compared to those who tried different forms of medication, who took between 6-9 months to see significant improvements. Patients don't need to go to hospital to receive treatment with rTMS; the simple procedure is performed in an outpatient clinic.

About  The London Psychiatry Centre

The London Psychiatry Centre offers an integrated and complete service addressing every need associated with mental health. This includes psychiatric, psychological, therapeutic and social aspects of a patient. Consultant Psychiatrists, Psychologists and Psychotherapists along with nutritionists, coaches, personal trainers and therapists are on site to help.

To find out more information about The London Psychiatry, visit the website - http://www.psychiatrycentre.co.uk.

References

1. Euba R, Poster presented at The Royal College of Psychiatrists' International Congress 2013

2. George M, Taylor J, Baron Short E, The expanding evidence base for rTMS treatment of depression, Current Opinion Psychiatry, 2013,26:13-18

3. O'Reardon JP, Solvason HB, Janicak PG, et al.Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007; 62:1208-1216.

4. Demitrack MA, Thase ME. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol Bull 2009; 42:5-38.

5. George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry 2010; 67:507-516.

6. McDonald WM, Durkalski V, Ball ER, et al.Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression. Depress Anxiety 2011; 28:973-980

7. Mantovani A, Pavlicova M, Avery D, et al.Long-term efficacy of repeated daily prefrontal transcranial magnetic stimulation (TMS) in treatment-resistant depression. Depress Anxiety 2012; 29:883-890

8. The London Psychiatry Centre data on file

9. Ludescher B, Machann J, Eschweiler GW, Thamer C, Maenz C, Hipp A, Claussen CD, & Schick F (2011). Active depression is associated with regional adiposity in the upper abdomen and the neck. International journal of psychiatry in medicine, 41 (3), 271-80 PMID: 22073766 [http://www.ncbi.nlm.nih.gov/pubmed/22073766 ]

10. Rubin RR, Gaussoin SA, Peyrot M, DiLillo V, Miller K, Wadden TA, West DS, Wing RR, Knowler WC, & Look AHEAD Research Group (2010). Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetologia, 53 (8), 1581-9 PMID: 20422396 [http://www.ncbi.nlm.nih.gov/pubmed/20422396 ]

11. Rutledge T, Linke SE, Krantz DS, Johnson BD, Bittner V, Eastwood JA, Eteiba W, Pepine CJ, Vaccarino V, Francis J, Vido DA, & Merz CN (2009). Comorbid depression and anxiety symptoms as predictors of cardiovascular events: results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Psychosomatic medicine, 71 (9), 958-64 PMID: 19834049 [http://www.ncbi.nlm.nih.gov/pubmed/19834049 ]

12. Shah AJ, Veledar E, Hong Y, Bremner JD, & Vaccarino V (2011). Depression and history of attempted suicide as risk factors for heart disease mortality in young individuals. Archives of general psychiatry, 68 (11), 1135-42 PMID: 22065529 [http://www.ncbi.nlm.nih.gov/pubmed/22065529 ]

13. George M, Taylor J, Baron Short E, The expanding evidence base for rTMS treatment of depression, Current Opinion Psychiatry, 2013,26:13-18

14. Li CT, Wang SJ, Hirvonen J, et al. Antidepressant mechanism of add-on repetitive transcranial magnetic stimulation in medication-resistant depression using cerebral glucose metabolism. J Affect Disord. 2010, 127(1-3):219-29

15. Blumberger DM, Mulsant BH, Fitzgerald PB, et al. A randomized double-blind sham-controlled comparison of unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant major depression. World J Biol Psychiatry. 2012;13(6):423-35

16. Fitzgerald PB, Hoy K, Gunewardene R, et al. A randomized trial of unilateral and bilateral prefrontal cortex transcranial magnetic stimulation in treatment-resistant major depression. Psychol Med. 2010;41:1187-1196

17. Galletly C, Gill S, Clarke P, Burton C, Fitzgerald PB. A randomized trial comparing repetitive transcranial magnetic stimulation given 3 days/week and 5 days/week for the treatment of major depression: is efficacy related to the duration of treatment or the number of treatments? Psychol Med. Sep 13 2011:1-8.

18. Holtzheimer PE, 3rd, McDonald WM, Mufti M, et al. Accelerated repetitive transcranial magnetic stimulation for treatment-resistant depression. Depress Anxiety. Oct 2010;27(10):960-963.

19. Carpenter LL, Janicak PG, Aaronson ST, Boyadjis T, Brock DG, Cook IA, Dunner DL, Lanocha K, Solvason HB, Demitrack MA. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012;29(7):587-96.

20. Connolly KR, Helmer A, Cristancho MA, Cristancho P, O'Reardon JP. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center. J Clin Psychiatry. 2012;73(4):e567-73.

21. Eranti S, Mogg, et al. [http://www.ncbi.nlm.nih.gov/pubmed/17202547 ] A Randomized, Controlled Trial with 6-Month Follow-Up of Repetitive Transcranial Magnetic Stimulation and Electroconvulsive Therapy for Severe Depression". American Journal of Psychiatry, 2007164 (1): 73-81

22. Coverage Policy Analysis: Repetitive Transcranial Magnetic Stimulation (rTMS), The New England Comparative Effectiveness Public Advisory Council, completed by: The Institute for Clinical and Economic Review. June 2012

SOURCE The London Psychiatry Centre

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Intelligent Automation is now one of the key business imperatives for CIOs and CISOs impacting all areas of business today. In his session at 21st Cloud Expo, Brian Boeggeman, VP Alliances & Partnerships at Ayehu, will talk about how business value is created and delivered through intelligent automation to today’s enterprises. The open ecosystem platform approach toward Intelligent Automation that Ayehu delivers to the market is core to enabling the creation of the self-driving enterprise.
"At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We're here to tell the world about our cloud-scale infrastructure that we have at Juniper combined with the world-class security that we put into the cloud," explained Lisa Guess, VP of Systems Engineering at Juniper Networks, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Enterprise architects are increasingly adopting multi-cloud strategies as they seek to utilize existing data center assets, leverage the advantages of cloud computing and avoid cloud vendor lock-in. This requires a globally aware traffic management strategy that can monitor infrastructure health across data centers and end-user experience globally, while responding to control changes and system specification at the speed of today’s DevOps teams. In his session at 20th Cloud Expo, Josh Gray, Chie...
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, discussed how to use Kubernetes to set up a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace. H...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Consumers increasingly expect their electronic "things" to be connected to smart phones, tablets and the Internet. When that thing happens to be a medical device, the risks and benefits of connectivity must be carefully weighed. Once the decision is made that connecting the device is beneficial, medical device manufacturers must design their products to maintain patient safety and prevent compromised personal health information in the face of cybersecurity threats. In his session at @ThingsExpo...
SYS-CON Events announced today that Grape Up will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company specializing in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the U.S. and Europe, Grape Up works with a variety of customers from emergi...
Detecting internal user threats in the Big Data eco-system is challenging and cumbersome. Many organizations monitor internal usage of the Big Data eco-system using a set of alerts. This is not a scalable process given the increase in the number of alerts with the accelerating growth in data volume and user base. Organizations are increasingly leveraging machine learning to monitor only those data elements that are sensitive and critical, autonomously establish monitoring policies, and to detect...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
SYS-CON Events announced today that Massive Networks will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Massive Networks mission is simple. To help your business operate seamlessly with fast, reliable, and secure internet and network solutions. Improve your customer's experience with outstanding connections to your cloud.
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
Everything run by electricity will eventually be connected to the Internet. Get ahead of the Internet of Things revolution and join Akvelon expert and IoT industry leader, Sergey Grebnov, in his session at @ThingsExpo, for an educational dive into the world of managing your home, workplace and all the devices they contain with the power of machine-based AI and intelligent Bot services for a completely streamlined experience.
Because IoT devices are deployed in mission-critical environments more than ever before, it’s increasingly imperative they be truly smart. IoT sensors simply stockpiling data isn’t useful. IoT must be artificially and naturally intelligent in order to provide more value In his session at @ThingsExpo, John Crupi, Vice President and Engineering System Architect at Greenwave Systems, will discuss how IoT artificial intelligence (AI) can be carried out via edge analytics and machine learning techn...